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What’s already known about this topic? 
• Surgical management of dermatofibrosarcoma protuberans (DFSP) includes 
wide local excision with or without margin control. 
• Although Mohs micrographic surgery (MMS), or similar margin-controlled 
excision is advocated in the UK, this appears to be based on consensus 
guidance and low-quality data, with few centres routinely providing this 
expertise. 
 
What does this study add? 
• This is the largest case series of DFSP reported from the UK to date with three 
quarters of the 483 primary DFSP treated between 2004 and 2014 being 
managed with wide local excision (WLE). 
• 6 local recurrences were found in the WLE group and 0 in the MMS group. 
• In individuals with primary DFSP who underwent WLE, complete histological 
clearance occurred less frequently at the first attempt (81.4%) compared to 






Background: Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer. 
Standard treatment in the United Kingdom (UK) is either surgical wide local excision 
(WLE) or Mohs micrographic surgery (MMS). It is unclear which approach has the 
lower recurrence rate.  
 
Objectives: We undertook a retrospective comparative review of DFSP surgical 
management in the UK National Health Service (NHS) in order to define: 
1) current surgical practice for primary and recurrent DFSP 
2) local recurrence rates for primary DFSP 
3) survival outcomes for DFSP.  
 
Methods: Retrospective clinical case-note review of patients with histologically-
confirmed DFSP (January 2004–2014) who have undergone surgical treatment.  
 
Results: Surgical management of 483 primary and 64 recurrent DFSP in 11 plastic 
surgery and 15 dermatology departments was analysed. Almost 75% of primary DFSP 
(n=362) were treated with WLE and 20.1% (n=97) with MMS. For recurrent DFSP, 
68.7% (n=44) and 23.4% (n=15) underwent WLE and MMS, respectively. Recurrent 
primary DFSP occurred in 6 patients after WLE and none after MMS. Median follow-
up was 4.8 years [IQR 3.5, 5.8] with 8 reported deaths during the follow-up analysis 
period; one confirmed to be DFSP-related.  
 
Conclusions: WLE was the commonest surgical modality used to treat DFSP across 
the UK. The local recurrence rate was very low, occurring only after WLE. Although a 
prospective RCT may provide more definitive outcomes, in the absence of a clearly 
superior surgical modality, treatment decisions should be based on patient preference, 






Dermatofibrosarcoma protuberans (DFSP) is a rare slow-growing cutaneous 
sarcoma. Reported annual incidence from large epidemiological studies in the 
USA and Denmark is 4-5 cases per million population per year1,2,3. In England 
incidence is 2.6 per million4, likely an underestimate because non-melanoma skin 
cancers are under-reported5.  
Surgical excision is the only recognised curative treatment for primary DFSP.  
However, after excision with apparently uninvolved histological margins, local 
recurrence within or adjacent to the primary site can occur. This is believed to be due 
to its infiltrative growth pattern and sampling error from standard histological 
processing,6 for which the specimen margin evaluated can range from 0.5%7 to 2%8.  
The amount of tissue visualized depends on the number of sections read. Surgical 
techniques utilising margin control such as Mohs micrographic surgery (MMS) may 
reduce the risk of sampling error.  
Evidence regarding surgical management of DFSP comprises small case-series 
that do not enable clinicians or patients to make informed treatment decisions: 
there are no randomised studies, and little long-term follow-up data. Conventional 
treatment is wide local excision (WLE) with 1 cm to 5 cm surgical margins of 
clinically uninvolved skin. The deep margin is defined anatomically and is normally 
at least to deep fascia. Reported recurrence rates after WLE range from 0 to 60%.9-
16,20,21 MMS limits excision to histologically involved tissue and an undefined 
surgical margin of uninvolved tissue peripherally and deeply – the size of this is 
not standardised for DFSP and depends on individual operators. MMS is reported 
to achieve recurrence rates of 0% to 8.3%.9,15,17-25 However, these data are based 
on retrospective and/or non-comparative studies that are heterogeneous in design 
and subject to bias.28 The British Society for Dermatological Surgery (BSDS) and 
European consensus guidelines state that MMS is the preferred treatment for 
DFSP.28,29 Two systematic reviews30,31 suggest that MMS or similar margin control 
techniques may be associated with lower recurrence rates but found no 
comparative data confirming that MMS conserves disease-free tissue.30  
Because of this uncertainty, we have reviewed UK NHS data relating to the 




Study Design  
A retrospective clinical case-note review of histologically confirmed DFSP between 
January 1st 2004 and December 31st 2013 was undertaken. UK clinicians were invited 
to participate via the UK Dermatology Clinical Trials Network (UK DCTN), British 
Association of Dermatologists (BAD) and the Reconstructive Surgical Trials Network 
(RSTN). Data were collected locally at individual Trusts by the team of DFSP 
collaborators. Approval was obtained from NHS Trust Research & Development 
departments. Clinicopathologic data included: demographic data, clinical history of 
lesion, tumour site, surgical/ therapeutic/ histopathologic details, post-operative events 
and available follow-up information (Supplementary Appendix 1). Cases treated with 
MMS included use of both frozen and paraffin embedded tissue sections. Data were 
anonymised. Patients who had surgery and any adjuvant or neoadjuvant treatment 
(chemotherapy or radiotherapy) were included in the overall patient cohort, but 
excluded from analysis of the surgical outcomes as additional treatment would have 
had a confounding effect. The statistical analysis protocol was published on the Centre 




As this was a retrospective study, data on cosmesis, function, patient reported 
outcome measures (PROMS) were not collected as this information was not 
systematically recorded in clinical case notes. However, to evaluate the patient 
perspective, an anonymous survey (Survey MonkeyTM) was sent to patients with prior 
history of DFSP via the DFSP Facebook page / www.thedfspnetwork.org 
[Supplementary Appendix 5]. 
 
Outcomes: 
Primary outcome: Three year local recurrence rate for primary DFSP, following MMS 
and WLE.  
 
Secondary outcomes: 
• Time to first recurrence (date of surgery to date of histologically confirmed local 
recurrence) 
• Histological clearance (histologic clearance following surgery and of post-
operative complication rates) 
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• Time to metastases (calculated from date of surgery to date of confirmed distant 
metastases) 
• Number of surgical procedures required to achieve adequate histological 
   clearance 
• Post-operative complication rate 
• Distant recurrence-free survival 
• Recurrence free survival  
 
Statistical analysis 
Age at diagnosis was calculated from date of diagnostic biopsy or - if not provided – 
date of surgery or multidisciplinary team discussion (whichever was earliest). The last 
follow-up was taken as last known clinical review or date of death. Follow-up duration 
was calculated as time from date of surgery to date of last known clinical review. 
Contributors were individually contacted for additional information regarding 
incomplete or unclear data in order to maximise completeness of datasets. Analysis 
queries were clarified following discussion with a second team member (RM). 
Demographic and clinicopathologic data were reported for MMS and WLE groups. 
Means (SDs) or medians (IQRs) were used for continuous data and percentages for 
categorical data.  Analyses were conducted separately for primary and recurrent 
DFSP. Results have been reported descriptively. 
 
Results 
Data were collected from 26 centres (11 plastic surgery and 15 dermatology) with 
representation from England, Scotland, Wales and Northern Ireland (Supplementary 
Appendix 2).  Clinicopathologic data were provided for 603 patients, of which 56 were 
excluded because of duplication, treatment outside data collection period or unclear 
histology or surgical details (Supplementary Appendix 3). Those undergoing 
procedures other than WLE or MMS, and those who had adjuvant chemotherapy or 
radiotherapy were excluded from analysis of surgical outcomes.  
 
Demographic, tumour and surgical outcome data for primary and recurrent DFSP are 
presented in Tables 1 and 2 respectively.  
 






Table 2: Demographic data for recurrent DFSP cases 
 
Overall, 74.9% (n=362/483) of primary DFSP and 68.7% (n=44/64) of recurrent DFSP 
patients underwent WLE compared to 20% (n=97/483) and 23.4% (n=15/64) 
respectively who underwent MMS. Details of tumours with fibrosarcomatous change 
are detailed in Supplementary Appendix 4. 
 
Primary DFSP cases (n=483) 
 
Primary outcome: Local recurrence rate at 3 years 
For primary DFSP, median follow up duration was 25.5months [IQR6.8,45.7]. 
Median follow up for WLE cases was 26.7 months [IQR 7.8, 48.2] and 14.2 
months [IQR 4.6, 35.6] for MMS. Follow up data were missing for 3% (n=11/362) 
WLE and 6.2% (n=6/97) MMS cases. There were six recurrences over the period 
of the data collection (Table 3). 
 
Table 3: Clinicopathological data for six cases of recurrence in the Primary 
DFSP cohort (all cases treated with WLE). 
 
All cases of recurrence followed WLE compared with zero recurrences in the MMS 
group. Median follow up for the 6 cases was 2 years [IQR 0.57-3.71]. 
 
Secondary outcomes: 
a) Time to first recurrence 
Mean time to first recurrence (n=6) was 37.2 months (range 9 – 76 months). 
b) Histological clearance 
Histological clearance following WLE was achieved with the first attempt at curative 
surgery in 81.4% (n=289/355) of patients; 10.1% had involved margins (n=36/355) and 
6.8% (n=24/355) were reported as ‘close’. Data were unclear or missing for the 
remaining 1.7% (n=6/355). For MMS, 86.6% (n=84/97) DFSP were reported as 
histologically ‘clear’ at the first surgical attempt, 3.1% (n=3/97) had ‘involved’ or ‘close’ 
margins. Data were unclear for 10.3% (n=10/97).  In the WLE group, patients were 
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less likely to have achieved histological clearance at the first attempt compared to 
those who had MMS. 
c)   Number of surgical procedures to achieve adequate histological 
clearance 
Median number of diagnostic procedures performed in both WLE (n=355) and 
MMS (n=97) groups was 1 [IQR 1,1]. Median number of therapeutic procedures in 
both of these groups was also 1 [IQR 1,1].  
Peripheral clinical margins used for WLE procedures were available for 274 
(77.2%) procedures. Median clinical margin was 3cm (n=136); range 0.5 – 5cm 
[Figure 1]. The number of MMS stages was reported in 72.2% (n=70) cases: 
median number of stages was 2 (average 1.9; range 1-4). Data for MMS margins 
used in the first layer was available in 36% (n=35): median margin 10mm (mean 
13; range 5-50).  
 
Figure 1. Range of WLE clinical margins used for all DFSP 
 
Pre-operative lesion and post-operative defect sizes for all DFSP groups, where 
available, are highlighted in Table 4. 
Table 4: Median pre-operative lesion size and post-operative defect size for 
all DFSP cases. 
 
Frozen sections were used in 36% (n=35) and slow Mohs in 32% (n=31) cases. 
The type of MMS sectioning was unknown for 33% (n=32). All cases with 
fibrosarcomatous change are detailed in Supplementary Appendix 4.  
d) Post-operative complications  
Data on post-operative complications were available for 88.2% (n=313/355) and 
71.2% (n=69/97) of WLE and MMS cases, respectively. Complications were reported 
following 15.8% (n=56/355) WLE and 9.3% (n=9/97) MMS procedures. Details of 
complications were missing for 5.4% (n=3/56) of the WLE group in whom a 
complication was reported. In the WLE group, 16% (n=9/56) reported more than one 
complication, compared to 11% (n=1/9) in the MMS group.  Most common 
complications following WLE included poor cosmetic outcome (50% of which required 
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further surgery), graft failure and infection (Table 5). Reported complications following 
MMS included poor cosmetic outcome and infection. 
 
Table 5. Reported complications following WLE in primary DFSP 
e)  Distant recurrence-free survival 
There were no reported cases of distant disease recurrence or death during follow-
up in this group. 
f) Recurrence-free survival 
There were no further reported loco-regional recurrences in this group. 
 
Recurrent DFSP cases (n=64) 
There were no reported locoregional recurrences after further treatment for recurrent 
DFSP cases in either WLE or MMS group during the data collection period. Median 
follow-up duration was 19.8 months [IQR 1.2,.44.4]. Median follow-up for WLE cases 
was30.8months [IQR 10.2,38.1] and 13.8 months [IQR 0.6, 21.1] for MMS cases. 
Follow up data were missing for 4.5% (n=2/44) of WLE and 6.7% (n=1/15) of MMS 
cases. 
Secondary Outcomes: 
a) Time to subsequent recurrence 
There were no further recurrences reported among 64 recurrent DFSP cases 
treated with WLE or MMS.  
b) Histological clearance 
Complete clearance was achieved for all DFSP cases treated with MMS (n=14).  
c) Number of surgical procedures to achieve adequate histological 
clearance 
Median number of diagnostic and independent therapeutic procedures for the 
recurrent DFSP tumours undergoing WLE (n=40) was 1 [IQR 1,1] and 2 [IQR 2,3], 
respectively. For the MMS group (n=14) this was also 1 [IQR 1,1] and 2 [IQR 2,3], 
respectively. The peripheral clinical margin size used for WLE was available for 
87.5% (n=35/40) procedures. Median clinical margin was 3cm (n=15; range 1-5 
cm) [Figure 1]. The number of MMS stages was reported in 78.6% (n=11/14) 
cases; the median number was 2 (mean 1.6; range 1-2). Data for margins used for 
the first MMS layer was only available in 14.4% (n=2); 10 and 15mm. Data on the 
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pre and post-operative lesion/defect sizes for the two recurrent groups are shown 
in Table 4. 
d) Post-operative complication rate 
Data on post-operative complications was available for 87.5% (n=35/40) and 
64.3% (n=9/14) of WLE and MMS procedures respectively. Complications 
occurred in 35% (n=14/40) WLE and 21.4% (n=3/14) MMS patients. Four patients 
(28.6%) who had a complication following WLE experienced more than one 
complication, compared to 33.3% (n=1) patient in the MMS group. The most 
common complications following WLE were infection, functional impairment and 
poor cosmetic outcome requiring further surgery. In the MMS group complications 
included infection (managed with a topical antibiotic) and chronic functional pain. 
d) Distant recurrence-free survival 
There were no reported cases of distant disease recurrence or death during follow 
up in this group. 
e) Recurrence-free survival 
There were no further reported locoregional recurrences in this group. 
 
Evaluation of the Patient Perspective 
To evaluate the patient perspective, an anonymous survey (Survey MonkeyTM) was 
sent to patients with prior history of DFSP via the DFSP Facebook page / 
www.thedfspnetwork.org [Supplementary Appendix 5]. Fifty-two patients reported a 
history of primary DFSP (March 1995 - June 2014).  One-third underwent >3 surgical 
procedures (44% of all procedures were MMS). Local recurrence occurred in six 
patients treated with WLE (time to recurrence 1 – 9.5 years). Satisfactory cosmetic 
outcome was reported in 50% (16/32) treated with WLE and 71% (12/17) with MMS 
(Chi-square p value 0.17). Half of individuals treated with WLE (16/32) would choose 
the same procedure again, compared with 94% (15/16) of those treated with MMS (Chi 
square p value 0.008). Eleven individuals who would not choose WLE again, cited 
MMS as their preferred alternative option. Amongst this selected group of responders, 




To our knowledge, this is the largest DFSP case series reported from the UK 
describing routine surgical DFSP management of 603 patients over a 10-year period 
in 26 UK NHS centres. WLE was undertaken in 74.9% (n=362/483) and 68.7% 
(n=44/64) of primary and recurrent DFSP cases respectively. Median follow-up for the 
primary cases was 2.2 years with all 6 cases of local recurrence occurring in the WLE 
group. The difference in local recurrence rates between WLE and MMS was 6 versus 
0. The median follow-up was 27 months for WLE versus 14.5 months for MMS for 
primary DFSP, and 31 months versus 14 months for recurrent DFSP. 
 
Two large population-based studies for DFSP from the USA1,3 have used cancer 
registries providing large datasets, but individual case-specific data are lacking. A 
more recent retrospective review using data from the Netherlands Cancer Registry 
with linked pathology demonstrated high rates of incomplete surgical excisions.27 
Variations in healthcare systems, costs and accessibility to treatment in different 
countries may affect external validity of these databases which is the reason for 
undertaking this multi-centred study which is the largest cohort reported from the UK. 
 
While consensus guidelines for the treatment of DFSP are available28,29,32,33 significant 
variations exist between healthcare systems. The US NCCN guidelines recommend 
WLE with peripheral margins of 2 – 4cm or MMS, with deep margins extending to the 
level of the investing fascial layer.31 European guidelines29 recommend MMS and 
“related variants” over WLE, with excision of the deep fascia and peripheral safety 
excision margins of 1 to 1.3 cm, preferably using slow Mohs. If WLE and standard 
histopathological procedures are used, a larger peripheral safety margin of 3 cm is 
recommended. Danish guidelines support WLE with 2 – 3cm peripheral margins and 
deep margins to include the deep fascia, or MMS as first-line treatment in ‘appropriate’ 
patients.32 The British Society for Dermatological Surgery (BSDS) advocates MMS as 
the preferred treatment for DFSP, but does not offer guidance on initial peripheral 
margin size or deep margin depth.28 Our results show that WLE is the commonest 
treatment for DFSP in the UK NHS. However, since 2011 when the BSDS position 
statement was published, MMS has been used more frequently; 43.3% (n=42) of all 
MMS cases were undertaken from 2012 onwards, compared with 25.4% (n=92) 
managed by WLE. Nonetheless, for both WLE and MMS in the UK, our data show a 
clear lack of consistency in deployment of these 2 surgical procedures. MMS for DFSP 
is similar to MMS used for BCC, but there are differences, and it has not been 
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standardized for DFSP. Although 34.8% (n=39) of MMS procedures in this cohort were 
performed using frozen sections, paraffin processing is generally recommended due 
to difficulties in distinguishing DFSP from scarring and reactive fibroblast proliferation. 
However, there are no comparative quality data for these 2 techniques. The reasons 
for variation in surgical practice in the UK are unclear.  
 
There were some trends demonstrated in our data which support that previously 
reported in smaller cohort studies. Head and neck DFSP were more commonly treated 
by MMS (38% of primary tumours and 44% of recurrent tumours). Moreover, half of 
tumour recurrences occurred on the head and neck raising a proposal that certain 
anatomical sites might benefit from margin control prior to reconstruction.  
 
Study limitations 
A limitation of retrospective studies is incomplete data, partly due to transfer of 
patients between different hospitals for diagnosis, treatment and follow-up and 
varying DFSP management pathways within different geographic areas. Archiving of 
older case notes limited access to historical records. Initial diagnostic, peri-operative 
and follow-up information was sometimes lacking. The median follow-up period for 
WLE was 67.8  and 78.1 months versus 36.2 and 35.1 months for MMS for primary 
and recurrent DFSP respectively, which will impact on detecting recurrence rates 
which frequently occur after 2 years. Taken together, all these factors may have 
resulted in an underestimation of the overall recurrence rate. Nonetheless, our study 
provides the largest dataset to report surgical management of DFSP in the UK.  
 
Data regarding pre-operative lesion size and post-operative defect size, albeit 
incomplete, warrants comment; the final defect size for both modalities does not 
appear to be critically different.  While the missing data is in part due to information 
not being accessible, in many cases it appears not to have been consistently 
recorded in medical/operative notes at the time of surgery. Without clear 
documentation of pre- and post-operative, lesion and defect size, and surgical 
margins used, obtaining accurate and consistent data on tissue conservation is not 
feasible. The same applies to post-operative function. 
 
The small number of recurrences reported in our series together with short follow-up 
times did not allow for calculation of distant disease-free and recurrence-free 
survival. Furthermore the study was underpowered to detect any significant 
differences between the groups and we have only been able to report the data 
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descriptively. Finally, there is likely to be selection bias in a retrospective study 
comparing two different treatments: without randomisation, the relative efficacy of 
one over the other cannot reliably be determined. The reasons for choosing WLE 
versus MMS were not explored specifically but are likely to include local availability of 
MMS, waiting times and lesion-specific factors. In a systematic review, Foroozan et 
al31 made a weak recommendation in favour of MMS or similar techniques with 
surgical margin control, but also highlighted the need for future randomised 
controlled trials (RCTs). However, development of sufficiently powered RCTs pose 
significant challenges for rare, largely non-life limiting disease with low recurrence 
rates such as DFSP and are unlikely to attract competitive funding. In the absence of 
any clearly superior surgical modality, treatment decisions should be based on 
patient preference, expertise of the treating team, and cost. Knowledge of the cost of 
WLE compared to MMS to the UK NHS for DFSP is lacking. There are significant 
cost differences dependent on setting e.g. local anaesthetic day-case costs versus 
general anaesthetic procedures with overnight stay and a robust health economic 
analysis is essential. In terms of establishing patient preferences, evaluation of both 
surgical options using validated patient reported outcome measure tools and 
development of an Option GridTM decision aid could help both clinicians and patients 
in the decision-making process.   
 
Cooperation between the UK Dermatology Clinical Trials Network (UK DCTN), the 
Reconstructive Surgical Trials Network (RSTN) and the National Cancer Research 
Institute (NCRI) Non-melanoma Skin Cancer Subgroup enabled this review to be 
undertaken. The development of UK consensus guidelines for the management of 
DFSP and other primary skin sarcomas has been approved and is scheduled for 
development during 2021-2. 
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